Brain health entered Davos as an economic priority, framed through Brain Capital and prevention. The analysis examines where policy ambition now outpaces biological evidence and measurement readiness.

Neurolief’s Proliv Rx receives FDA Premarket Approval for depression, marking a rare Class III clearance for a home-use neuromodulation device and following closely after Flow’s FDA entry.

BrainCo’s $280m round places a non-implant EEG company among the most highly funded BCIs. The case highlights how China enables scale before markets fully mature and what that means for global competition.

The UK is aligning ARIA funding, Cambridge NeuroWorks, and NHS reforms to advance non-invasive neurotech, closing the early-stage innovation gap and using national health infrastructure to validate and scale wearables.

ARPA-H has launched EVIDENT, a $100M program to build quantitative measurement systems and data infrastructure for mental health, linking rapid-acting treatments to objective, longitudinal clinical evidence.

UNESCO has adopted the first global neurotechnology ethics standard, treating neural data as sensitive, banning sleep-based manipulation, and setting strict limits for workplace and classroom use as neurotech enters consumer products.

As neurotechnology moves into consumer markets, U.S. lawmakers are proposing new protections for brain-derived data, signaling a shift in how neural signals are treated under privacy law.

China is moving to industrialise brain–computer interfaces at a national scale, combining state funding, coordinated regulation, and parallel clinical development in an effort to compete with U.S.-led neurotech ecosystems.